Publication | Open Access

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Phase I/iia TrialMammalian TargetOncologyHealth SciencesMedicineClinical TrialsPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyRapamycin Inhibitor Ridaforolimus